BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma
Results equate to an objective response rate (CRs and PRs) of 63%
Data from an earlier cutoff date in February are included in an abstract published today by the European Hematology Association (EHA) 2025 conference
LUND, SE / / May 14, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces latest updated data from the ongoing Phase 2a study of BI-1206 in combination with rituximab and Calquence® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL). Additionally today, an abstract containing data from an earlier February cutoff date has been published by the European Hematology Association (EHA) as part of its 2025 congress due to take place June 12-15 in Milan, Italy.
The data released today show the first eight patients in the triple combination arm of BioInvent's ongoing Phase 2a in non-Hodgkin's lymphoma. All patients exhibited disease control at first assessment (DCR 100%), and results show an overall objective response rate of 63% with two patients achieving a complete response (CR) and three patients with partial responses (PR). Stable disease (SD) was observed in the three remaining patients. The combination has been well tolerated in all patients treated at the cut-off-date. These data are further updated compared to the data included in the EHA abstract.
"We continue to be encouraged by the early data demonstrating robust clinical activity and manageable safety profile in the ongoing triple combination arm of the Phase 2a study of BI-1206 in combination with rituximab and Calquence in NHL patients who have relapsed after previous lines of treatment," said Martin Welschof, Chief Executive Officer of BioInvent. "The objective responses observed to date highlight the potential of the combination to improve outcomes and overcome resistance, a result we believe is driven by the mechanism of action of BI-1206. Previously we have demonstrated that BI-1206 can restore response to rituximab in relapsed/refractory patients. Now we demonstrate that a BTK inhibitor may be added to this combination without compromising safety. We look forward to advancing the clinical development of this promising and highly convenient treatment."
Details of the EHA abstract released today are below:
Title: BI-1206, an Antibody Targeting FcγRIIB, given in Combination with Rituximab and Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin's LymphomaLead Author: Laura Fogliatto, Hospital de Clínicas de Porto Alegre, Porto Alegre, BrazilAbstract Number: PB3180
About the studyThe triple combination arm in the ongoing Phase 2a study combines the subcutaneous formulation of BI-1206 and rituximab with Calquence® (acalabrutinib) in subjects with indolent B-cell non-Hodgkin's lymphoma (NHL) relapsed or refractory to rituximab. Approximately 30 patients are expected to be enrolled in Spain, Germany, the US, and Brazil. In February 2024 BioInvent signed a clinical supply agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to provide Calquence® for the combination arm.
About BI-1206BI-1206 is one of BioInvent's lead drug candidates and is developed to re-establish the clinical effect of existing cancer treatments such as pembrolizumab and rituximab. The drug candidate is evaluated in two separate clinical programs, one for the treatment of non-Hodgkin's lymphoma (NHL, a type of blood cancer) and one for the treatment of solid tumors.
About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)Co. Reg. No.: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 50www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-14 15:30 CEST.
Attachments
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the treatment of non-Hodgkin's lymphoma
SOURCE: BioInvent International
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 minutes ago
- Business Wire
Madison Square Garden Entertainment Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Results
NEW YORK--(BUSINESS WIRE)--Madison Square Garden Entertainment Corp. (NYSE: MSGE) ('MSG Entertainment' or the 'Company') today reported financial results for the fiscal fourth quarter and full-year ended June 30, 2025. Fiscal 2025 was highlighted by another year of strong demand for the Company's array of live entertainment offerings. The Company hosted nearly 6 million guests at more than 975 events, including concerts, special events, family shows, and marquee sports, as well as the New York Knicks' ("Knicks") and New York Rangers' ("Rangers") regular seasons and the Knicks' playoff run. It also reflected approximately 1.1 million tickets sold across 200 shows of the Christmas Spectacular production, which delivered another year of record-setting revenues. In addition, the Company repurchased approximately $40 million of its Class A common stock during fiscal 2025. For fiscal 2025, the Company reported revenues of $942.7 million, a decrease of $16.5 million, or 2%, as compared to the prior year. In addition, the Company reported operating income of $122.1 million, an increase of $10.2 million, or 9%, and adjusted operating income of $222.5 million, an increase of $11.0 million, or 5%, both as compared to the prior year. (1) For the fiscal 2025 fourth quarter, the Company reported revenues of $154.1 million, a decrease of $31.9 million, or 17%, as compared to the prior year quarter. In addition, the Company reported an operating loss of $25.8 million, an increase of $16.9 million as compared to the prior year quarter, and an adjusted operating loss of $1.3 million as compared to adjusted operating income of $13.1 million in the prior year quarter. (1) Executive Chairman and CEO James L. Dolan said, 'During fiscal 2025, we saw strong demand for our portfolio of entertainment assets. We see this momentum continuing in fiscal 2026, and believe we are well positioned to drive solid revenue and adjusted operating income growth in the year ahead.' Results for the Three and Twelve Months Ended June 30, 2025 and 2024: Note: Amounts may not foot due to rounding. NM — Absolute percentages greater than 200% and comparisons from positive to negative values or to zero values are considered not meaningful. (1) See page 4 of this earnings release for the definition of adjusted operating income (loss) included in the discussion of non-GAAP financial measures. Expand Entertainment Offerings, Arena License Fees and Other Leasing Fiscal 2025 fourth quarter revenues from entertainment offerings of $118.7 million decreased $24.1 million, or 17%, as compared to the prior year quarter, primarily due to lower event-related revenues and a decrease in revenues subject to the sharing of economics with Madison Square Garden Sports Corp. ("MSG Sports") pursuant to the Arena License Agreements. Event-related revenues decreased $21.6 million, primarily due to lower revenues from concerts, partially offset by higher revenues from other live entertainment and sporting events held at the Company's venues. The decrease in revenues from concerts primarily reflects a decrease in the number of concerts at the Madison Square Garden Arena ("The Garden") and lower per-concert revenues, primarily due to a shift in the mix of events at The Garden from promoted events to rentals, partially offset by an increase in the number of concerts at the Company's theaters, all as compared to the prior year quarter. The increase in revenues from other live entertainment and sporting events primarily reflects higher per-event revenues. Revenues subject to the sharing of economics with MSG Sports pursuant to the Arena License Agreements decreased $2.4 million, primarily due to lower suite license fee revenues (excluding those retained by MSG Entertainment) as compared to the prior year quarter, which mainly reflects the impact of fewer Knicks and Rangers games played at The Garden. Fiscal 2025 fourth quarter arena license fees and other leasing revenues of $9.0 million increased $0.5 million, or 6%, as compared to the prior year quarter, primarily due to an increase in other leasing revenues, partially offset by lower arena license fees due to a combined one fewer Knicks and Rangers regular season game played at The Garden as compared to the prior year quarter. Fiscal 2025 fourth quarter direct operating expenses associated with entertainment offerings, arena license fees and other leasing of $85.5 million decreased $14.2 million, or 14%, as compared to the prior year quarter, primarily due to lower event-related expenses and, to a lesser extent, lower expenses related to the sharing of economics with MSG Sports pursuant to the Arena License Agreements, partially offset by an increase in expenses related to the presentation of the Christmas Spectacular production and other cost increases. Event-related expenses decreased $15.7 million, mainly due to lower per-concert expenses, primarily due to a shift in the mix of events at The Garden from promoted events to rentals, and a decrease in the number of concerts at The Garden, partially offset by an increase in the number of concerts at the Company's theaters, all as compared to the prior year. This was partially offset by higher expenses for other live entertainment and sporting events as compared to the prior year quarter. Expenses associated with the sharing of economics with MSG Sports pursuant to the Arena License Agreements decreased $1.8 million, reflecting a proportional decrease in contractual revenue sharing as a result of the decrease in suite license fee revenues. Food, Beverage and Merchandise Fiscal 2025 fourth quarter food, beverage and merchandise revenues of $26.4 million decreased $8.3 million, or 24%, as compared to the prior year quarter. This decrease was primarily due to (i) lower food and beverage sales at Knicks and Rangers games, primarily due to fewer games played at The Garden as compared to the prior year quarter, partially offset by higher per-event revenues, and (ii) lower food and beverage sales at concerts, primarily due to a decrease in the number of concerts at The Garden, partially offset by an increase in the number of concerts at the Company's theaters, both as compared to the prior year quarter. Fiscal 2025 fourth quarter food, beverage and merchandise direct operating expenses of $16.5 million decreased $6.2 million, or 27%, as compared to the prior year quarter, primarily due to lower food and beverage costs at concerts at the Company's venues and lower food and beverage costs at Knicks and Rangers games at The Garden. Selling, General and Administrative Expenses Fiscal 2025 fourth quarter selling, general and administrative expenses of $59.9 million increased $4.1 million, or 7%, as compared with the prior year quarter. This increase was primarily due to higher employee compensation and related benefits, partially offset by lower rent expense and other net cost decreases. Operating Loss and Adjusted Operating (Loss) Income Fiscal 2025 fourth quarter operating loss of $25.8 million increased $16.9 million and adjusted operating income decreased $14.4 million to an adjusted operating loss of $1.3 million, both as compared to the prior year quarter, primarily due to the decrease in revenues and, to a lesser extent, higher selling, general and administrative expenses, partially offset by lower direct operating expenses. About Madison Square Garden Entertainment Corp. Madison Square Garden Entertainment Corp. (MSG Entertainment) is a leader in live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The Company's portfolio includes a collection of world-renowned venues – New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre – that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the Company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for more than 90 years. More information is available at Non-GAAP Financial Measures We define adjusted operating income (loss), which is a non-GAAP financial measure, as operating income (loss) excluding (i) depreciation, amortization and impairments of property and equipment, goodwill and other long-lived assets, including right of use assets and related lease costs, (ii) share-based compensation expense or benefit, (iii) restructuring charges or credits, (iv) merger, spin-off, and acquisition-related costs, including merger-related litigation expenses, (v) gains or losses on sales or dispositions of businesses and associated settlements, (vi) the impact of purchase accounting adjustments related to business acquisitions, (vii) amortization for capitalized cloud computing arrangement costs and (viii) gains and losses related to the remeasurement of liabilities under the executive deferred compensation plan. We exclude impairments of long-lived assets, including right-of-use assets and related lease costs, as these expenses do not represent core business operating results of the Company. We believe that the exclusion of share-based compensation expense or benefit allows investors to better track the performance of our business without regard to the settlement of an obligation that is not expected to be made in cash. We eliminate merger, spin-off, and acquisition-related transaction costs, when applicable, because the Company does not consider such costs to be indicative of the ongoing operating performance of the Company as they result from an event that is of a non-recurring nature, thereby enhancing comparability. In addition, management believes that the exclusion of gains and losses related to the remeasurement of liabilities under the executive deferred compensation plan, provides investors with a clearer picture of the Company's operating performance given that, in accordance with U.S. generally accepted accounting principles, gains and losses related to the remeasurement of liabilities under the executive deferred compensation plan are recognized in Operating (income) loss whereas gains and losses related to the remeasurement of the assets under the executive deferred compensation plan, which are equal to and therefore fully offset the gains and losses related to the remeasurement of liabilities, are recognized in Other income (expense), net, which is not reflected in Operating income (loss). We believe adjusted operating income (loss) is an appropriate measure for evaluating the operating performance of the Company on a consolidated basis. Adjusted operating income (loss) and similar measures with similar titles are common performance measures used by investors and analysts to analyze our performance. Internally, we use revenues and adjusted operating income (loss) as the most important indicators of our business performance, and evaluate management's effectiveness with specific reference to these indicators. Adjusted operating income (loss) should be viewed as a supplement to and not a substitute for operating income (loss), net income (loss), cash flows from operating activities, and other measures of performance and/or liquidity presented in accordance with GAAP. Since adjusted operating income (loss) is not a measure of performance calculated in accordance with GAAP, this measure may not be comparable to similar measures with similar titles used by other companies. For a reconciliation of operating income (loss) to adjusted operating income (loss), please see page 5 of this release. Forward-Looking Statements This press release may contain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that any such forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties, and that actual results, developments or events may differ materially from those in the forward-looking statements as a result of various factors, including financial community perceptions of the Company and its business, operations, financial condition and the industries in which it operates and the factors described in the Company's filings with the Securities and Exchange Commission, including the sections titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' contained therein. The Company disclaims any obligation to update any forward-looking statements contained herein. Conference Call Information: ADJUSTMENTS TO RECONCILE OPERATING INCOME (LOSS) TO ADJUSTED OPERATING INCOME (LOSS) (in thousands) (Unaudited) The following is a description of the adjustments to operating (loss) income in arriving at adjusted operating (loss) income as described in this earnings release: Depreciation and amortization. This adjustment eliminates depreciation and amortization of property and equipment and intangible assets. Impairment of long-lived assets. This adjustment eliminates the impairment of long-lived assets, including right of use assets and related lease costs. Share-based compensation. This adjustment eliminates the compensation expense relating to restricted stock units, performance stock units and stock options granted to employees and non-employee directors. Restructuring charges. This adjustment eliminates costs related to termination benefits provided to certain corporate executives and employees. Merger, spin-off, and acquisition-related costs. This adjustment eliminates costs related to mergers, spin-offs and acquisitions, including merger-related litigation expenses. Amortization for capitalized cloud computing arrangement costs. This adjustment eliminates amortization of capitalized cloud computing arrangement costs. Remeasurement of deferred compensation plan liabilities. This adjustment eliminates the impact of gains and losses related to the remeasurement of liabilities under the executive deferred compensation plan. CONSOLIDATED BALANCE SHEETS (unaudited) (in thousands) June 30, 2025 2024 ASSETS Current Assets: Cash, cash equivalents and restricted cash $ 43,538 $ 33,555 Accounts receivable, net 66,781 77,259 Related party receivables, current 22,487 17,469 Prepaid expenses and other current assets 104,326 90,801 Total current assets 237,132 219,084 Non-Current Assets: Property and equipment, net 621,075 633,533 Right-of-use lease assets 484,544 388,658 Goodwill 69,041 69,041 Indefinite-lived intangible assets 63,801 63,801 Deferred tax assets, net 54,072 68,307 Other non-current assets 140,177 110,283 Total assets $ 1,669,842 $ 1,552,707 LIABILITIES AND DEFICIT Current Liabilities: Accounts payable, accrued and other current liabilities $ 184,360 $ 203,750 Related party payables, current 23,830 42,506 Long-term debt, current 30,469 16,250 Operating lease liabilities, current 35,100 27,736 Deferred revenue 228,642 215,581 Total current liabilities 502,401 505,823 Non-Current Liabilities: Long-term debt, net of deferred financing costs 568,780 599,248 Operating lease liabilities, non-current 566,484 427,014 Other non-current liabilities 45,477 43,787 Total liabilities 1,683,142 1,575,872 Commitments and contingencies Deficit: Class A Common Stock (a) 461 456 Class B Common Stock (b) 69 69 Additional paid-in capital 44,843 33,481 Treasury stock at cost (5,483 and 4,365 shares as of June 30, 2025 and June 30, 2024, respectively) (180,204 ) (140,512 ) Retained earnings 153,034 115,603 Accumulated other comprehensive loss (31,503 ) (32,262 ) Total deficit (13,300 ) (23,165 ) Total liabilities and deficit $ 1,669,842 $ 1,552,707 Expand ______________________ (a) Class A Common Stock, $0.01 par value per share, 120,000 shares authorized; 46,076 and 45,556 shares issued as of June 30, 2025 and June 30, 2024, respectively. (b) Class B Common Stock, $0.01 par value per share, 30,000 shares authorized; 6,867 shares issued as of June 30, 2025 and June 30, 2024. Expand SELECTED CASH FLOW INFORMATION (in thousands) (Unaudited) Twelve Months Ended June 30, 2025 2024 Net cash provided by operating activities $ 115,297 $ 111,266 Net cash used in investing activities (23,693 ) (62,371 ) Net cash used in financing activities (81,621 ) (99,695 ) Net increase (decrease) in cash, cash equivalents and restricted cash 9,983 (50,800 ) Cash, cash equivalents and restricted cash, beginning of period 33,555 84,355 Cash, cash equivalents and restricted cash, end of period $ 43,538 $ 33,555 Expand
USA Today
an hour ago
- USA Today
These are the wealthiest suburbs of America's biggest cities
New York's wealthiest suburb is Scarsdale, a name long linked to affluence. Wellesley, the most well-heeled Boston suburb, is known for academia. McLean, a high-earner enclave outside the nation's capital, houses diplomats and spies. Fewer Americans might recognize the name of Hinsdale, Chicago's wealthiest suburb. And some non-Texans might struggle to differentiate between University Park and West University Place, the most affluent suburbs, respectively, of metropolitan Dallas and Houston. A new report from the personal finance site GOBankingRates identifies the wealthiest suburbs of America's 50 largest metropolitan areas in 2025. It's a spinoff from an earlier analysis, which listed the wealthiest suburbs in America. Some of the names are familiar. The nation's wealthiest suburb is Scarsdale, a storied suburb in New York's leafy Westchester County. New York state, California and Texas are home to eight of the 10 wealthiest suburbs in America, Census data show. Other affluent suburbs attract little attention outside their own regions. A 'Jeopardy!' contestant might be hard-pressed, for example, to identify Alamo as the wealthiest suburb of San Francisco. "I wasn't really familiar with Milton, Georgia, until the survey," said Rudri Patel, a senior financial expert at GOBankingRates, referring to the wealthiest Atlanta suburb. "I think affluence is moving beyond stereotyped geographic regions," such as Beverly Hills, she said. "It doesn't need to be 90210." To compile the report, researchers found the suburb with the highest mean household income for each of the 50 largest metropolitan areas. Communities of fewer than 5,000 households were omitted. Here are the wealthiest suburbs of the largest cities Here, then, are the wealthiest suburbs of the 20 largest U.S. metropolitan areas. New York: Scarsdale. This famous New York suburb boasts an average household income of $601,193, as of 2023. The average Scarsdale home is worth $1.6 million, as of June 2025. It's the wealthiest suburb in America. Los Angeles: Palos Verdes Estates. Forget Beverly Hills: Palos Verdes Estates, part of the tony Palos Verdes Peninsula, is the wealthiest L.A. suburb and the 11th wealthiest in the nation. Household incomes average $367,178. Home values average $2.8 million. Chicago: Hinsdale. Most people associate Chicago's North Shore with suburban wealth, but the city's wealthiest suburb (and the nation's eighth wealthiest) sits to the west. Hinsdale has an average household income of $376,366. Home values average $1.3 million. Dallas-Fort Worth: University Park. The nation's sixth-wealthiest suburb is named for Southern Methodist University. The average household income is $389,868, and home values average $2.4 million. Houston: West University Place. This unsung suburb of Houston, named for nearby Rice University, is the nation's third wealthiest. Average household income is $409,677. The average home value is $1.1 million. Washington, D.C.: McLean. The most affluent D.C. suburb ranks 12th nationally. The average household income is $364,591, and home prices average $1.7 million. Philadelphia: Ardmore. This Main Line Philly suburb does not rank among the nation's 50 wealthiest, but Ardmore residents are doing just fine. Average household income is $161,029, and home prices average $527,016. Atlanta: Milton. This suburb wasn't incorporated until 2006, although its namesake, John Milton, fought in the Revolutionary War. Milton does not rank among the nation's 50 wealthiest suburbs. Household income averages $225,532, and the average home is worth $976,830. Miami: Pinecrest. You don't hear much about the nation's 21st wealthiest suburb, which sits south of Miami. Household incomes average $312,591, and home values average $2.4 million. Phoenix: Scottsdale. Though technically a suburb, Scottsdale is larger than many central cities, with a population of 241,361 in 2020. Scottsdale does not rank among the nation's 50 wealthiest suburbs. Household income averages $168,679, and home values average $946,327. Boston: Wellesley. The nation's 10th wealthiest suburb is home to Wellesley and Babson colleges. Household incomes average $368,179, and home values average $2.1 million. San Francisco: Alamo. Technically a suburb of Oakland, Alamo sits in Contra Costa County, east of San Francisco. Household incomes average $403,334. Home values average $2.5 million. Alamo is the nation's fifth wealthiest suburb. Riverside-San Bernardino, California: Eastvale. Who knew the Inland Empire ranked as the 13th largest metro area in America? As for Eastvale, it's an enclave of former dairy farms, incorporated in 2010. Household income averages $177,404, and home prices average $965,438. Detroit: Birmingham. Grosse Pointe may be more famous, but Birmingham is Detroit's wealthiest suburb, with an average household income of $240,711 and an average home value of $822,581. Birmingham does not rank among the nation's 50 wealthiest suburbs. Seattle: Mercer Island. The wealthiest Seattle suburb is an actual island, east of the city. It ranks 29th nationally. Household incomes average $303,425, and home values average $2.5 million. Minneapolis-Saint Paul: Edina. One of the first Minneapolis suburbs, Edina was once reachable by streetcar. Household incomes average $205,682, and home values average $785,567. Like most of the remaining suburbs on this list, Edina does not rank among the 50 wealthiest U.S. suburbs. San Diego: Solana Beach. With average home values of $2.6 million, Solana Beach is one of the most expensive suburbs in America. The average household income is a more modest $216,465. Tampa-St. Petersburg: Keystone. This little-known suburb ranks as the wealthiest in Tampa-St. Pete, with an average household income of $199,755. The average home value is only $277,636. Denver: Greenwood Village. Denver's wealthiest suburb was settled, fittingly, by gold prospectors. Household incomes average $258,780, and home prices average a whopping $1.6 million. Baltimore: Annapolis Neck. This waterfront community is technically a suburb of Annapolis, the Maryland capital. The average household income is $240,059, and home values average $665,302. Beyond the top 20: Other wealthiest suburbs Didn't see your city in the top 20? Here are the wealthiest suburbs of some other large metros. St. Louis: Clayton. Average household income: $216,884. Average home value: $1.1 million. Portland, Oregon: Cedar Mill. Average household income: $223,012. Average home value: $796,226. Pittsburgh: Franklin Park. Average household income: $218,236. Average home value: $502,695. Cincinnati: Mason. Average household income: $161,798. Average home value: $565,612. Cleveland: Solon. Average household income: $186,260. Average home value: $461,665. Indianapolis: Zionsville. Average household income: $220,563. Average home value: $666,102. Nashville, Tennessee: Brentwood. Average household income: $261,248. Average home value: $1.4 million. Milwaukee: Mequon. Average household income: $209,904. Average home value: $669,603.
Business Wire
an hour ago
- Business Wire
IFF Launches POWERFRESH ® ACE 2000, a Bread Fresh-Keeping Solution That ‘Aces' the Shelf-Life Test
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announces the launch of POWERFRESH® ACE 2000 to the U.S. market. This next-generation fresh-keeping enzyme solution is designed to help industrial bakeries deliver bread with improved softness, resilience and cohesiveness throughout shelf life — meeting specific consumer demands while improving operational efficiency. 'Developed by IFF's biosciences experts, this advancement underscores our commitment to helping bakeries deliver exceptional value and maintain a competitive edge in the industry,' said Clementina Dellomonaco, senior vice president of food biosciences at IFF. 'Whenever we enhance the consumer experience, we help our customers build stronger brand equity, drive repeat purchases and unlock long-term growth.' As ingredient prices rise and consumer expectations for long-lasting freshness continue to grow, U.S. bakeries face unprecedented pressure to maintain product quality without increasing operational strain. A recent survey shows that 60% of U.S. consumers would buy bread marketed as 'fresher for longer,' and more than half expect at least four days of freshness at purchase. 1 POWERFRESH® ACE 2000 addresses these priorities by improving softness and resilience for up to 34 days, while reducing waste and inventory complexity. In IFF-led trials, POWERFRESH® ACE 2000 demonstrated a strong performance across both white and whole-wheat bread applications. This enzyme consistently delivered superior resilience while maintaining structure and visual appeal, even at lower dosage levels compared to market alternatives, resulting in stable loaves with excellent texture and mouthfeel. Crucially, it preserved the soft, yet easy-to-butter texture that consumers prefer, even several days after purchase. 'As a staple food, bread is a regular fixture in consumers' baskets — so expectations for quality are high and constant,' said Emily Wagener, industry leader for food and beverage enzymes for North America at IFF. 'At the same time, bakeries face challenges that require smarter solutions. POWERFRESH® ACE 2000 is bakers' ally to deliver high-quality products with the delicious texture and freshness consumers expect, every time.' As the latest addition to IFF's established POWERFRESH® portfolio, this new solution offers a smarter path to consistent bread quality and efficiency — whether used in new formulations or to optimize existing ones. Improved product resilience enables industrial bakeries to extend distribution and better manage shelf-life targets. These operational gains also align with sustainability goals by reducing waste, minimizing returns and optimizing resources across the supply chain. Learn more about POWERFRESH® ACE 2000 and IFF's innovative bakery enzyme portfolio here. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products — advancing wellness, delighting the senses and enhancing the human experience. Learn more at LinkedIn, Instagram and Facebook. ©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
